Skip to main content

4 Pharma Industry Arguments Against CMS Drug Pricing Plan

Theresa Carnegie, Lauren Moldawer, and Hassan Shaikh co-authored an article published by Law360 on the Inflation Reduction Act's Medicare drug pricing negotiation program. 

The authors wrote, "While the parameters of this program are established in statute, Congress directed the Centers for Medicare & Medicaid Services to work out the details. CMS released initial and revised policy guidance on the negotiation program for comment earlier this year. It also released the list of 10 drugs selected for inclusion in the negotiation program for 2026 at the end of August."